NU-MED PLUS, INC. (OTCMKTS:NUMD) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
See Item 9.01, Exhibit 99.
The information contained in this Item 7.01 and in Exhibit 99 is being furnished, and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under such Section 18. Furthermore, the information contained in this Item 7.01 and in Exhibit 99 shall not be deemed to be incorporated by reference into our filings under the Securities Act or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
(a)
Exhibits.
Exhibit No.
Description
Press Release dated June 27, 2017.
Nu-Med Plus, Inc. ExhibitEX-99 2 numedpatentapprovalpr.htm PRESS RELEASE DATED JUNE 27,…To view the full exhibit click here About NU-MED PLUS, INC. (OTCMKTS:NUMD)
NU-MED PLUS, INC. (NU-MED) is an early stage company, which is engaged in developing, manufacturing and marketing technologies in the medical device field. The Company intends to become a medical device company principally engaged in the design, development, enhancement and commercialization of beginning, early, and selective later-stage medical devices. The Company focuses on the creation of a nitric oxide powder formulation, a hospital bedside nitric oxide generator and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community around the world. NU-MED has developed a prototype lightweight Portable NO Delivery System that can be worn by patients outside of the hospital setting for underserved chronic therapies, and for applications within the United States and in developing nations. The Company has not generated any revenues.
